Amneal Pharmaceuticals, Class Stock Working Capital

AMRX Stock

USD 8.15 0.06 0.74%

Amneal Pharmaceuticals, Class fundamentals help investors to digest information that contributes to Amneal Pharmaceuticals,'s financial success or failures. It also enables traders to predict the movement of Amneal Stock. The fundamental analysis module provides a way to measure Amneal Pharmaceuticals,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amneal Pharmaceuticals, stock.

	Last Reported	Projected for Next Year
Net Working Capital	531.3 M	750.4 M
Change In Working Capital	-47.2 M	-49.5 M

Net Working Capital is likely to rise to about 750.4 M in 2024, whereas Change In Working Capital is likely to drop (49.5 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Amneal Pharmaceuticals, Class Company Working Capital Analysis

Amneal Pharmaceuticals,'s Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Amneal Pharmaceuticals, Working Capital

531.27 M

Most of Amneal Pharmaceuticals,'s fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amneal Pharmaceuticals, Class is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Amneal Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Amneal Pharmaceuticals, is extremely important. It helps to project a fair market value of Amneal Stock properly, considering its historical fundamentals such as Working Capital. Since Amneal Pharmaceuticals,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amneal Pharmaceuticals,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amneal Pharmaceuticals,'s interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.88	-0.95	0.89	-0.28	0.69	0.91	0.84	0.93	-0.78	0.93	0.65	0.94	0.32	0.92	0.24	0.37	0.96	0.86	0.73	0.6	0.96	0.85	0.25	-0.21
Total Stockholder Equity	0.88		-0.85	0.73	0.1	0.82	0.79	0.64	0.74	-0.64	0.8	0.33	0.8	0.02	0.76	-0.01	0.06	0.93	0.67	0.65	0.25	0.84	0.79	0.04	0.01
Net Tangible Assets	-0.95	-0.85		-0.96	0.43	-0.74	-0.98	-0.91	-0.94	0.9	-0.97	-0.71	-0.98	-0.43	-0.96	-0.29	-0.48	-0.99	-0.93	-0.87	-0.68	-0.99	-0.87	-0.34	0.3
Net Debt	0.89	0.73	-0.96		-0.57	0.62	0.99	0.94	0.95	-0.96	0.97	0.81	0.98	0.53	0.96	0.35	0.58	0.92	0.92	0.91	0.72	0.95	0.8	0.33	-0.3
Retained Earnings	-0.28	0.1	0.43	-0.57		-0.02	-0.5	-0.63	-0.52	0.6	-0.49	-0.81	-0.49	-0.81	-0.5	-0.63	-0.83	-0.27	-0.61	-0.55	-0.85	-0.42	-0.23	-0.58	0.6
Accounts Payable	0.69	0.82	-0.74	0.62	-0.02		0.65	0.46	0.52	-0.59	0.65	0.2	0.63	0.07	0.52	0.03	0.1	0.8	0.58	0.67	0.18	0.67	0.52	0.12	-0.09
Long Term Debt	0.91	0.79	-0.98	0.99	-0.5	0.65		0.95	0.95	-0.95	0.98	0.78	0.99	0.48	0.98	0.31	0.53	0.95	0.92	0.92	0.7	0.97	0.85	0.33	-0.29
Net Receivables	0.84	0.64	-0.91	0.94	-0.63	0.46	0.95		0.95	-0.9	0.94	0.86	0.96	0.52	0.97	0.33	0.58	0.85	0.9	0.85	0.83	0.92	0.81	0.38	-0.31
Good Will	0.93	0.74	-0.94	0.95	-0.52	0.52	0.95	0.95		-0.84	0.98	0.86	0.98	0.51	0.98	0.42	0.57	0.9	0.92	0.79	0.78	0.96	0.81	0.34	-0.32
Short Term Investments	-0.78	-0.64	0.9	-0.96	0.6	-0.59	-0.95	-0.9	-0.84		-0.89	-0.73	-0.91	-0.5	-0.9	-0.26	-0.55	-0.84	-0.85	-0.95	-0.69	-0.87	-0.78	-0.33	0.28
Long Term Debt Total	0.93	0.8	-0.97	0.97	-0.49	0.65	0.98	0.94	0.98	-0.89		0.82	0.99	0.49	0.98	0.41	0.54	0.95	0.93	0.88	0.72	0.97	0.81	0.32	-0.31
Capital Surpluse	0.65	0.33	-0.71	0.81	-0.81	0.2	0.78	0.86	0.86	-0.73	0.82		0.8	0.77	0.82	0.71	0.81	0.61	0.82	0.72	0.87	0.73	0.51	0.45	-0.51
Total Liab	0.94	0.8	-0.98	0.98	-0.49	0.63	0.99	0.96	0.98	-0.91	0.99	0.8		0.49	0.99	0.35	0.55	0.95	0.94	0.87	0.73	0.98	0.86	0.35	-0.31
Short Long Term Debt	0.32	0.02	-0.43	0.53	-0.81	0.07	0.48	0.52	0.51	-0.5	0.49	0.77	0.49		0.5	0.88	1.0	0.3	0.69	0.52	0.68	0.46	0.24	0.81	-0.88
Total Current Assets	0.92	0.76	-0.96	0.96	-0.5	0.52	0.98	0.97	0.98	-0.9	0.98	0.82	0.99	0.5		0.35	0.55	0.92	0.93	0.84	0.76	0.97	0.89	0.36	-0.32
Treasury Stock	0.24	-0.01	-0.29	0.35	-0.63	0.03	0.31	0.33	0.42	-0.26	0.41	0.71	0.35	0.88	0.35		0.87	0.2	0.53	0.35	0.55	0.32	0.05	0.61	-0.8
Short Term Debt	0.37	0.06	-0.48	0.58	-0.83	0.1	0.53	0.58	0.57	-0.55	0.54	0.81	0.55	1.0	0.55	0.87		0.36	0.74	0.55	0.73	0.51	0.3	0.81	-0.87
Intangible Assets	0.96	0.93	-0.99	0.92	-0.27	0.8	0.95	0.85	0.9	-0.84	0.95	0.61	0.95	0.3	0.92	0.2	0.36		0.88	0.82	0.57	0.97	0.87	0.26	-0.2
Common Stock	0.86	0.67	-0.93	0.92	-0.61	0.58	0.92	0.9	0.92	-0.85	0.93	0.82	0.94	0.69	0.93	0.53	0.74	0.88		0.82	0.81	0.95	0.81	0.64	-0.6
Property Plant Equipment	0.73	0.65	-0.87	0.91	-0.55	0.67	0.92	0.85	0.79	-0.95	0.88	0.72	0.87	0.52	0.84	0.35	0.55	0.82	0.82		0.61	0.82	0.68	0.33	-0.32
Current Deferred Revenue	0.6	0.25	-0.68	0.72	-0.85	0.18	0.7	0.83	0.78	-0.69	0.72	0.87	0.73	0.68	0.76	0.55	0.73	0.57	0.81	0.61		0.71	0.6	0.59	-0.56
Net Invested Capital	0.96	0.84	-0.99	0.95	-0.42	0.67	0.97	0.92	0.96	-0.87	0.97	0.73	0.98	0.46	0.97	0.32	0.51	0.97	0.95	0.82	0.71		0.9	0.41	-0.35
Net Working Capital	0.85	0.79	-0.87	0.8	-0.23	0.52	0.85	0.81	0.81	-0.78	0.81	0.51	0.86	0.24	0.89	0.05	0.3	0.87	0.81	0.68	0.6	0.9		0.35	-0.22
Capital Stock	0.25	0.04	-0.34	0.33	-0.58	0.12	0.33	0.38	0.34	-0.33	0.32	0.45	0.35	0.81	0.36	0.61	0.81	0.26	0.64	0.33	0.59	0.41	0.35		-0.96
Long Term Investments	-0.21	0.01	0.3	-0.3	0.6	-0.09	-0.29	-0.31	-0.32	0.28	-0.31	-0.51	-0.31	-0.88	-0.32	-0.8	-0.87	-0.2	-0.6	-0.32	-0.56	-0.35	-0.22	-0.96

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Amneal Pharmaceuticals,

Working Capital Over Time

Amneal Capital Surpluse

Capital Surpluse

648.25 Million

At this time, Amneal Pharmaceuticals,'s Capital Surpluse is fairly stable compared to the past year.

In accordance with the company's disclosures, Amneal Pharmaceuticals, Class has a Working Capital of 531.27 M. This is 24.81% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 64.06% higher than that of the company.

Amneal Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amneal Pharmaceuticals,'s direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amneal Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing Amneal Pharmaceuticals, by comparing valuation metrics of similar companies.

Amneal Pharmaceuticals, is currently under evaluation in working capital category among its peers.

Amneal Pharmaceuticals, ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amneal Pharmaceuticals,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amneal Pharmaceuticals,'s managers, analysts, and investors.

Environmental

Governance

Social

Amneal Fundamentals

	Return On Equity	-1.86
	Return On Asset	0.0594
	Profit Margin	(0.07) %
	Operating Margin	0.12 %
	Current Valuation	5.08 B
	Shares Outstanding	309.84 M
	Shares Owned By Insiders	52.19 %
	Shares Owned By Institutions	46.48 %
	Number Of Shares Shorted	4.48 M
	Price To Earning	230.50 X
	Price To Book	86.10 X
	Price To Sales	1.40 X
	Revenue	2.39 B
	Gross Profit	791.46 M
	EBITDA	500.78 M
	Net Income	(48.72 M)
	Cash And Equivalents	87.33 M
	Cash Per Share	0.58 X
	Total Debt	2.75 B
	Current Ratio	1.74 X
	Book Value Per Share	(0.30) X
	Cash Flow From Operations	345.58 M
	Short Ratio	4.12 X
	Earnings Per Share	(0.86) X
	Price To Earnings To Growth	(0.30) X
	Target Price	10.5
	Number Of Employees	7.85 K
	Beta	1.18
	Market Capitalization	3.76 B
	Total Asset	3.47 B
	Retained Earnings	(490.18 M)
	Working Capital	531.27 M
	Current Asset	753.39 M
	Current Liabilities	310.2 M
	Net Asset	3.47 B

About Amneal Pharmaceuticals, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Amneal Pharmaceuticals, Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amneal Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amneal Pharmaceuticals, Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC